Celularity, Inc. (NASDAQ:CELU) Shares Shorted: Short Interest Down 52.3% in September

Posted by Stanley Muller on Oct 14th, 2026

Celularity, Inc. (NASDAQ:CELU – Get Free Report) saw a large decline in short interest in September. As of September 30th, there was short interest totaling 391,276 shares, a decline of 52.3% from the September 15th total of 821,020 shares. Approximately 1.6% of the company’s stock are sold short. Based on an average daily volume of 154,929 shares, the short-interest ratio is presently 2.5 days.

Celularity Stock Performance

Shares of CELU traded down $0.11 on Wednesday, hitting $1.31. 47,821 shares of the stock traded hands, compared to its average volume of 1,363,318. Celularity has a one year low of $0.56 and a one year high of $2.55. The company has a market capitalization of $42.51 million, a PE ratio of -0.48 and a beta of 0.77. The business has a 50 day simple moving average of $1.25 and a 200 day simple moving average of $1.03.

Celularity (NASDAQ:CELU – Get Free Report) last released its quarterly earnings data on Tuesday, September 29th. The company reported $0.02 earnings per share (EPS) for the quarter. The business had revenue of $3.85 million during the quarter.

Wall Street Analyst Weigh In

Separately, Weiss Ratings raised shares of Celularity from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 27th. One research analyst has rated the stock with a Sell rating. According to MarketBeat.com, Celularity has an average rating of “Sell”.

View Our Latest Report on CELU

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in Celularity stock. C V Starr & Co. Inc. bought a new position in Celularity, Inc. (NASDAQ:CELU – Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 764,069 shares of the company’s stock, valued at approximately $1,582,000. Celularity comprises approximately 0.8% of C V Starr & Co. Inc.’s investment portfolio, making the stock its 4th biggest position. C V Starr & Co. Inc. owned 2.64% of Celularity at the end of the most recent quarter. Institutional investors own 19.02% of the company’s stock.

About Celularity

(Get Free Report)

Celularity, Inc is a biotechnology company focused on developing cell therapies and biomaterial products derived from human placental tissue. The company’s platform is designed to use the placenta as a scalable source of allogeneic cells and biomaterials for applications in oncology, immune-mediated diseases, infectious diseases and tissue repair.

Celularity’s development pipeline has included placental-derived natural killer cell programs, including CYNK-001, which has been evaluated for potential use in hematologic cancers and other diseases.